Baxter wins FDA nod for haemophilia A prophylaxis
This article was originally published in Scrip
Executive Summary
Baxter International gained the US FDA's blessing for Advate (antihemophilic factor, recombinant plasma/albumin free method) as a routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A.